D. E. Shaw & Co., Inc. Arcus Biosciences, Inc. Transaction History

D. E. Shaw & Co., Inc.

$107 Billion
Q3 2024

A detailed history of D. E. Shaw & Co., Inc. transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 13,501 shares of RCUS stock, worth $201,299. This represents 0.0% of its overall portfolio holdings.

Number of Shares

13,501

Holding current value

$201,299

% of portfolio

0.0%

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$13.69 - $18.01 $236,344 - $310,924	-17,264 Reduced 56.12%	13,501 $206,000
Q2 2024 Aug 14, 2024	SELL	$14.59 - $18.48 $536,576 - $679,638	-36,777 Reduced 54.45%	30,765 $468,000
Q1 2024 May 15, 2024	BUY	$14.83 - $20.18 $1 Million - $1.36 Million	67,542 New	67,542 $1.28 Million
Q2 2023 Aug 14, 2023	BUY	$16.97 - $22.03 $169,615 - $220,189	9,995 New	9,995 $202,000
Q4 2022 Feb 14, 2023	BUY	$19.7 - $35.71 $528,038 - $957,170	26,804 New	26,804 $554,000
Q2 2022 Aug 15, 2022	SELL	$17.23 - $37.73 $759,619 - $1.66 Million	-44,087 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$28.92 - $41.83 $8.36 Million - $12.1 Million	-288,907 Reduced 86.76%	44,087 $1.39 Million
Q4 2021 Feb 14, 2022	BUY	$31.38 - $48.47 $4.39 Million - $6.79 Million	140,031 Added 72.57%	332,994 $13.5 Million
Q3 2021 Nov 15, 2021	SELL	$26.93 - $37.68 $4.36 Million - $6.1 Million	-161,983 Reduced 45.64%	192,963 $6.73 Million
Q2 2021 Aug 16, 2021	SELL	$22.75 - $35.77 $4.65 Million - $7.31 Million	-204,363 Reduced 36.54%	354,946 $9.75 Million
Q1 2021 May 17, 2021	SELL	$26.16 - $41.39 $262,227 - $414,893	-10,024 Reduced 1.76%	559,309 $15.7 Million
Q4 2020 Feb 16, 2021	SELL	$17.0 - $32.36 $759,968 - $1.45 Million	-44,704 Reduced 7.28%	569,333 $14.8 Million
Q3 2020 Nov 16, 2020	BUY	$17.14 - $25.47 $2.89 Million - $4.3 Million	168,755 Added 37.9%	614,037 $10.5 Million
Q2 2020 Aug 14, 2020	BUY	$13.97 - $36.56 $6.22 Million - $16.3 Million	445,282 New	445,282 $11 Million
Q1 2020 May 15, 2020	SELL	$8.78 - $19.28 $290,618 - $638,168	-33,100 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$7.33 - $10.79 $242,623 - $357,149	33,100 New	33,100 $334,000

Others Institutions Holding RCUS

# of Institutions

200

Shares Held

51.5M

Call Options Held

236K

Put Options Held

141K

View Full List

About Arcus Biosciences, Inc.

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $1.08B
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

More about RCUS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account